In analyses of 23,572 colorectal cancer cases and 48,700 controls of East Asian descent, there was little evidence of association of genetically proxied ACE inhibition and colorectal cancer risk (OR 0.97, 95% CI 0.88 to 1.07; P = 0.59). This evidence concerns the gene ACE and colorectal cancer.